Business Wire

ALPEGA

12.3.2024 15:58:32 CET | Business Wire | Press release

Share
Alpega Hits New Heights: Exceeds 'Rule of 40' Milestone with Stellar 2023 Results

Alpega, a leading global logistics SaaS software company, proudly announces its remarkable achievements for the fiscal year 2023, significantly surpassing targets for the third consecutive year. Alpega exceeded revenue and EBITDA objectives underpinned by strong bookings and new business opportunities, which is testimony to the strong traction that the Alpega solutions have with our customers. This success marks a significant milestone as Alpega now surpasses the prestigious 'Rule of 40' territory, a hallmark of excellence for SaaS software companies.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240305956634/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Photo: Alpega)

"In 2023, our remarkable performance underscores Alpega's steadfast commitment to delivering exceptional value to our customers." declared Todd DeLaughter, Alpega CEO. "Our core competency lies in leveraging our extensive carrier-based assets to provide tangible benefits to both shippers and carriers across a diverse range of solutions in Execution, Planning, Sourcing and Payments. As the sole SaaS provider offering Transport Management Systems (TMS) for shippers alongside an 80,000-strong open carrier network, covering approximately 10% of all commercial trucks in Europe, we lead the charge in innovation and efficiency. With these carriers connected through three premier freight exchanges in Europe, boasting strong leadership in Iberia, Romania, and Central and Southeastern European countries, we offer unparalleled connectivity and efficiency, facilitating the seamless matching of available freight loads with transportation capacity."

Alpega's ability to consistently exceed expectations and achieve such remarkable milestones is a testament to its unwavering dedication to excellence and customer satisfaction. As the company continues to push boundaries and redefine industry standards, it remains poised for even greater success in the years ahead.

Alpega

Alpega is a leading global logistics SaaS software company, dedicated to delivering end-to-end solutions that comprehensively address all transport requirements. Our mission is to empower shippers and carriers through efficient digitalization to meet today’s logistics challenges, driving smarter logistics for a greener tomorrow.

Drawing on extensive carrier-based assets, Alpega delivers tangible benefits across Execution, Planning, Sourcing and Payment solutions. As the sole SaaS provider offering Transport Management Systems (TMS) for shippers, coupled with an 80,000-strong open carrier network covering around 10% of all commercial trucks in Europe, we are at the forefront of innovation and efficiency. For our carriers, our connectivity extends through three premier freight exchanges in Europe, with notable leadership in Iberia, Romania, Central, and Southeastern European regions, facilitating seamless matching of freight loads with transportation capacity.

With over three decades of expertise in transportation, we empower businesses to streamline their supply chain planning and execution, resulting in reduced costs and heightened visibility. Alpega's suite of solutions synergistically generates added value for our customers. Our community comprises 80,000 carriers and 200,000 members, seamlessly connected electronically each day to efficiently manage vital transport operations. Operating in 80 countries globally, Alpega boasts a diverse team of over 600 professionals representing 31 nationalities.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240305956634/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye